JD-005

JD-005 is J & D Pharmaceuticals' investigational phosphatidylcholine-associated, liposomal formulation of salicylsalicylic acid, the active pharmaceutical ingredient used in the related JD-004 program. The company is developing oral and parenteral formulations for inflammatory and analgesic applications, including traumatic brain injury, operative pain, autosomal dominant polycystic kidney disease, and Hutchinson-Gilford progeria syndrome. J & D Pharmaceuticals states that the salicylic-acid active moiety competes with ATP at IκB kinase beta, reducing NF-κB signaling, while phosphatidylcholine association is intended to improve gastrointestinal safety. ([jdpharmaceuticals.com](https://jdpharmaceuticals.com/science/))

Other names

PC-associated salicylsalicylic acidsalicylsalicylic acid phosphatidylcholine